ArticleFrontiers in endocrinology2023

Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans.

A L De Sousa-Coelho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.